BURLINGTON, Mass., March 1 /PRNewswire-FirstCall/ -- Palomar Medical
Technologies, Inc. (Nasdaq: PMTI) announced today that the Palomar Lux1540
Fractional(TM) Laser Handpiece will be introduced at the American Academy of
Dermatology's 64th Annual Meeting in San Francisco from March 4th to 6th and
will be on hand for investor demonstrations. At that time, Management will be
available to discuss Palomar's full line of products at the San Francisco
Moscone Convention Center, booth #3139.
The new Palomar Lux1540 Fractional(TM) Laser Handpiece uses patented
fractional technology to create precisely defined zones of elevated
temperature within the tissue. By varying treatment parameters, diverse
effects can be induced in these zones with minimal damage to the surrounding
tissue. The advantage of such a device is its ability to create a pattern of
isolated columns of coagulation in the epidermis and dermis, without damage to
the tissue surrounding the columns. Location, shape and dimensions of these
columns can be accurately tuned to achieve the desired clinical effect. One
benefit of fractional technology over conventional bulk-treatment approaches
is that it provides an increased safety margin, resulting from the fact that a
large volume of tissue remains intact. At the same time, the surface-to-volume
ratio of the treated area is maximized, which may result in more effective
tissue healing and collagen remodeling. That, in turn, may lead to enhanced
smoothing of periorbital wrinkles and overall skin resurfacing. Equally
important, it means less discomfort and minimal downtime for the customer.
This handpiece is pending FDA clearance for soft tissue coagulation, and
Palomar intends to seek additional clearances for skin resurfacing, wrinkles,
pigmented lesions such as lentigines, melasma and dyschromia, and others. The
Lux1540 is an attachment for the popular StarLux(R) Pulsed Light and Laser
System which offers hair removal, photofacials for pigmented and vascular
lesions, acne treatment, leg vein clearance, and many other aesthetic
applications. Palomar plans to begin shipments of the Palomar Lux1540
Fractional(TM) Laser Handpiece this summer.
Chief Executive Officer Joseph P. Caruso commented, "We continue to be a
market leader in the development of new technology. For over eight years,
Palomar has been developing fractional technology to provide an effective,
safe, and versatile technique for phototreatment of various skin conditions.
We are pleased to present an expansion opportunity for those who wish to
capitalize on additional markets while offering flexibility and versatility at
a low cost."
To reserve a time to meet with Palomar management and/or receive product
demonstrations, please contact Palomar's Investor Relations' department at
781-993-2411 or ir@palomarmedical.com.
About Palomar Medical Technologies Inc: Palomar is a leading researcher
and developer of light-based systems for cosmetic treatments. Palomar
pioneered the optical hair removal field, when, in 1997, it introduced the
first high-powered laser hair removal system. Since then, many of the major
advances in light-based hair removal have been based on Palomar technology.
There are now millions of light-based cosmetic procedures performed around the
world every year in physician offices, clinics, spas and salons. Palomar is
testing many new and exciting applications to further advance the hair removal
market and other cosmetic applications. Palomar is uniquely focused on
developing proprietary light-based technology for introduction to the mass
markets. Palomar has an agreement with The Gillette Company to develop and
potentially commercialize a patented home-use, light-based hair removal device
for women, an agreement with Johnson & Johnson Consumer Companies to develop
and potentially commercialize home-use, light-based devices for reducing or
reshaping body fat including cellulite, reducing the appearance of skin aging,
and reducing or preventing acne, and was awarded a contract by the Department
of the Army to develop a light-based self-treatment device for
Pseudofolliculitis Barbae ("PFB").
For more information on Palomar and its products, visit Palomar's website
at http://www.palomarmedical.com. To continue receiving the most up-to-date
information and latest news on Palomar as it happens, sign up to receive
automatic e-mail alerts by going to the Investor Relations' section of the
website.
With the exception of the historical information contained in this
release, the matters described herein contain forward-looking statements,
including but not limited to statements relating to new markets, development
and introduction of new products, and financial projections that involve risk
and uncertainties that may individually or mutually impact the matters herein,
and cause actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but are not
limited to, results of future operations, technological difficulties in
developing or introducing new products, the results of future research, lack
of product demand and market acceptance for current and future products, the
effect of economic conditions, challenges in managing joint ventures and
research with third parties and government contracts, the impact of
competitive products and pricing, governmental regulations with respect to
medical devices, including whether FDA clearance will be obtained for future
products, the results of litigation, difficulties in collecting royalties,
potential infringement of third-party intellectual property rights, and/or
other factors, which are detailed from time to time in the Company's SEC
reports, including the report on Form 10-K for the year ended December 31,
2004 and the Company's quarterly reports on Form 10-Q. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. The Company undertakes no obligation to release
publicly the result of any revisions to these forward-looking statements that
may be made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
Contact: Kayla Castle
Investor Relations Manager
Palomar Medical Technologies Inc
781-993-2411
ir@palomarmedical.com
SOURCE Palomar Medical Technologies Inc
 back to top
Related links:
http://www.palomarmedical.com
Company News On-Call:
http://www.prnewswire.com/comp/107555.html
CONTACT:
Kayla Castle, Investor Relations Manager of
Palomar Medical Technologies Inc, +1-781-993-2411,
ir@palomarmedical.com
|
